Tharwat M, Tawheed A, El-Kassas M. Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients: The imperative for safety assessment studies. World J Clin Cases 2025; 13(9): 99043 [PMID: 40144486 DOI: 10.12998/wjcc.v13.i9.99043]
Corresponding Author of This Article
Mohamed El-Kassas, MD, Professor, Department of Endemic Medicine, Faculty of Medicine, Helwan University, Ain Helwan, Cairo 11795, Egypt. m_elkassas@hq.helwan.edu.eg
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Mar 26, 2025 (publication date) through Oct 23, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Tharwat M, Tawheed A, El-Kassas M. Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients: The imperative for safety assessment studies. World J Clin Cases 2025; 13(9): 99043 [PMID: 40144486 DOI: 10.12998/wjcc.v13.i9.99043]
World J Clin Cases. Mar 26, 2025; 13(9): 99043 Published online Mar 26, 2025. doi: 10.12998/wjcc.v13.i9.99043
Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients: The imperative for safety assessment studies
Mina Tharwat, Ahmed Tawheed, Mohamed El-Kassas
Mina Tharwat, Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Aswan University, Aswan 81528, Egypt
Ahmed Tawheed, Mohamed El-Kassas, Department of Endemic Medicine, Faculty of Medicine, Helwan University, Cairo 11795, Egypt
Author contributions: Tharwat M and Tawheed A wrote the manuscript and revised the manuscript; El-Kassas M designed the overall concept and outline of the manuscript; and all authors contributed to this article and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mohamed El-Kassas, MD, Professor, Department of Endemic Medicine, Faculty of Medicine, Helwan University, Ain Helwan, Cairo 11795, Egypt. m_elkassas@hq.helwan.edu.eg
Received: July 11, 2024 Revised: November 18, 2024 Accepted: December 2, 2024 Published online: March 26, 2025 Processing time: 153 Days and 10.1 Hours
Abstract
Hepatocellular carcinoma (HCC) is the most prevalent cancer of the hepatobiliary tract and the third leading cause of cancer-related mortality worldwide. Atezolizumab and bevacizumab combination is currently considered among the front-line treatment modalities for advanced unresectable HCC. Most studies examining this combination were focused on evaluating its effectiveness. Despite numerous case reports documenting some side effects, there is a limited number of large-scale studies assessing these side effects. In this article, we comment on the case report by Park et al published recently, reporting a fatal intra-tumoral hemorrhage in a patient with HCC who received systemic therapy in the form of the combination of atezolizumab and bevacizumab.
Core Tip: In this article, we comment on the case report by Park et al, published in the recently reporting a fatal intra-tumoral hemorrhage in a patient with hepatocellular carcinoma following successful treatment with atezolizumab/bevacizumab. Multiple predictive factors have been reported to be associated with such condition. They can be categorized as either patient-related (age, systemic hypertension, and use of anticoagulants), liver disease-related (degree of liver decompensation and thrombocytopenia), or tumor-related (portal vein thrombosis). However, future studies are required to assess the long-term safety of this combination in patients with hepatocellular carcinoma.
